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Abstract: INTRODUCTION: Helicobacter pylori infection (H pylori-I) affects more than half of the
global population and consists an important burden to public health and healthcare expenditures, by
contributing to many diseases’ pathogenesis. AIM: This study aimed to evaluate the current nonbismuth
quadruple eradication regimens in a high antibiotic resistance area, such as Greece, concerning their cost-
effectiveness, especially during financial crisis period. MATERIALS AND METHODS: Eight hundred
and nine patients who received eradication treatment against H pylori-I were included to evaluate five dif-
ferent regimens, using amoxicillin, clarithromycin, and metronidazole as antibiotics and one proton-pump
inhibitor, based on their current eradication rates. Regimes compared 10-day concomitant use of (a) pan-
toprazole or (b) esomeprazole; 10-day sequential use of (c) pantoprazole or (d) esomeprazole; and 14-day
hybrid using esomeprazole. Cost-effectiveness analysis ratio (CEAR) and incremental cost-effectiveness
ratios were calculated taking into account all direct costs and cases who needed second-line treatment.
Additionally, sensitivity analysis was performed to predict all potential combinations. RESULTS: Ten-
day concomitant regimen with esomeprazole was characterized by the lowest CEAR (179.17€) followed
by the same regimen using pantoprazole (183.27€). Hybrid regimen, although equivalent in eradication
rates, was found to have higher CEAR (187.42€), whereas sequential regimens were not cost-effective
(CEAR: 204.12€ and 216.02€ respectively). DISCUSSION: This is the first study evaluating the cost-
effectiveness of H pylori-I treatment regimens in a high clarithromycin-resistance (฀26.5%) European area,
suggesting the 10-day concomitant regimen with generics using esomeprazole 40 mg as the most appro-
priate one. National and regional guidelines should include cost-effectiveness in their statements, and
further studies are required to clarify the necessity of a wide ”test and treat” policy for H pylori-I.
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Esophagogastroduodenoscopy  77 
C13 Urea Breath Test (Helicobacter Test INFAI®) 30.36 
Gastric histology using Giemsa stain 27.76 
*Based on the resource costs supplied by the Greek National Organization for Health Care Benefits 
Provision  
    Hp-I; Helicobacter pylori infection 
 
